Evidence map›Paper›PMID 26926928›Full record

ArticleProstate cancer and prostatic diseases2016

Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.

A Sanchez, J D Schoenfeld, P L Nguyen, M Fiorentino, D Chowdhury, M J Stampfer, H D Sesso, E Giovannucci, L A Mucci, I M Shui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. A Review of Prostate Cancer Genome-Wide Association Studies (GWAS).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

A SanchezDepartment of Urology, Massachusetts General Hospital, Boston, MA, USA.
J D SchoenfeldDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
P L NguyenDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
M FiorentinoDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
D ChowdhuryDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
M J StampferDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
H D SessoDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
E GiovannucciDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
L A MucciDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
I M ShuiDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA.

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Validity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1991 to 2009
$41.8M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Physicians' Health Study II: Prevention Trial of VitaminsR01CA097193 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GAZIANO, J. MICHAEL · 2002 to 2011
$15.7M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
Energy Balance-Related Hormones & Prostate Cancer Incidence & ProgressionR01CA133891 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI GIOVANNUCCI, EDWARD · 2008 to 2012
$3.3M
Growth Factors and Lethal Prostate Cancer SignatureR01CA141298 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI STAMPFER, MEIR · 2010 to 2013
$2.2M
RANDOMIZED TRIAL OF ASPIRIN AND MORTALITYR01CA040360 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 2002
$775k
TRIAL OF ASPIRIN AND BETA-CAROTENE IN U S MD'SR01HL034595 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 1991
–
NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS R01 CA034944NCI NIH HHS R01 CA040360NCI NIH HHS R01 CA097193NCI NIH HHS R01 CA133891NCI NIH HHS R01 CA141298NCI NIH HHS T32 CA009001NCI NIH HHS UM1 CA167552NHLBI NIH HHS R01 HL026490NHLBI NIH HHS R01 HL034595
6 · The paper itself

Abstract

backgroundTo evaluate whether single-nucleotide polymorphisms (SNPs) reflecting common variation in the tumor suppressor BRCA1 affect prostate cancer outcomes. Because radiation therapy (RT) induces DNA damage, we hypothesized that common variation in BRCA1 has a role in progression to lethal prostate cancer, particularly in patients receiving RT.

methodsWe followed 802 men diagnosed with localized prostate cancer (cT1-T3/N0/M0) who were treated with RT in the US Health Professionals Follow-up Study (HPFS) and Physicians' Health Study (PHS), for progression to lethal prostate cancer. Six SNPs (rs3737559, rs1799950, rs799923, rs915945, rs4474733 and rs8176305) were genotyped in HPFS to capture common variation across BRCA1. rs4474733 and rs8176305 were also evaluated in the PHS cohort. Cox proportional hazards models were used to estimate per-allele hazard ratios (HR) and 95% confidence intervals (CI) stratified by primary treatment.

resultsIn the RT group (n=802), 71 men progressed to lethal disease during a mean follow-up of 12 years. We found that two SNPs, rs4473733 (HR: 0.65; 95% CI 0.42-0.99) and rs8176305 (HR: 2.03; 95% CI 1.33-3.10), were associated with lethal prostate cancer in men receiving RT.

conclusionsCommon variation in BRCA1 may influence clinical outcomes in patients receiving RT for localized prostate cancer by modifying the response to RT. Our findings merit further follow-up studies to validate these SNPs and better understand their functional and biological significance.

Indexed as

Genetic VariationAdultAgedAllelesBRCA1 ProteinCombined Modality TherapyDisease ProgressionDNA DamageFollow-Up StudiesGenotypeHumansMaleMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingBRCA1 Protein

Identifiers

PMID26926928
PMCPMC4865401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.